Key result
Pentazocine administration for chest pain relief in patients with acute myocardial infarction showed no significant difference in mortality compared to patients not requiring analgesics.
Why the study?
Does pentazocine affect mortality in patients with acute myocardial infarction admitted to a Coronary Care Unit?
Cohort (n=457)
Does pentazocine affect mortality in patients with acute myocardial infarction admitted to a Coronary Care Unit?
Pentazocine use for chest pain relief in acute myocardial infarction is not associated with increased mortality compared to patients not requiring analgesics.
No mortality signal with pentazocine in AMI; observational data leave comparative safety versus alternatives open for randomized study.
SummaryPentazocine does not cause the hypotension associated with the use of opiates in patients with myocardial infarction but some haemodynamic studies have suggested that the drug could be hazardous. An analysis is described of 457 consecutive patients admitted to a Coronary Care Unit, of whom 250 (55%) received pentazocine for relief of chest pain, while the remainder did not require analgesics and, therefore, acted as a control.Utilising a coronary prognostic index no significant difference in the mortality rate between the two groups was demonstrated, nor was the mortality dependent on the total dosage. Furthermore, no clinical disadvantage arose from the administration of pentazocine to patients with elevated systolic blood pressure on admission.
No takes yet. Share an insight, caveat, or question.
Lal et al. (1973) conducted a cohort in Acute myocardial infarction (n=457). Pentazocine vs. No analgesics was evaluated on Mortality rate. Pentazocine administration for chest pain relief in patients with acute myocardial infarction showed no significant difference in mortality compared to patients not requiring analgesics.
Synapse has enriched one closely related paper. Consider it for comparative context: